Using a single-cell RNA-sequencing platform, a new study demonstrates that EBV reprograms autoreactive B cells to drive lupus autoimmunity.

Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies for cancer, today announced the publication of a peer-reviewed study titled "Antibody?Gamma/Delta T ...

Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. | Third ...

Barr virus transforms B cells into inflammatory drivers that spark the widespread immune attacks seen in lupus.

Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient ...

Scientists from Stanford University have discovered that systemic lupus erythematosus is directly related to the Epstein–Barr virus (EBV), which is present in the body of almost every adult. This was ...

A new study has finally nailed down what links Epstein-Barr virus (EBV) – a pathogen that over 95 percent of adults worldwide ...

Although penile cancer represents less than 1% of male malignancies, it carries substantial physical and psychological burden ...

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved ...

When your body’s immune cells attack you instead of protecting you, today’s treatments tamp down the friendly fire but they ...

Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this ...

This advisory highlights more than 100 poster abstracts that will be presented at ASH 2025 involving researchers ...